Palo Alto, CA - Ranolazine (Ranexa TM) may be one step closer to FDA approval after showing that it can reduce weekly angina frequency compared with placebo in the Evaluation of Ranolazine in Chronic ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — In high-risk patients with implantable cardioverter defibrillators, ranolazine did not reduce the ...
Ranolazine is an antianginal drug and a class V antiarrhythmic drug that is mainly used for the treatment of chronic angina. Ranolazine is also used off-label to treat certain arrhythmias, including ...
Pulmonary Circulation, Vol. 5, No. 4 (December 2015), pp. 691-700 (10 pages) AbstractPulmonary arterial hypertension (PAH) causes right ventricular ischemia, dysfunction, and failure. PAH patients may ...
SAN FRANCISCO — The first prospective international randomized controlled study focusing specifically on angina in patients with diabetes has shown that ranolazine (Ranexa, Gilead Sciences) is an ...
ACC: Ranolazine Relieves Chest Pain in Type 2 Diabetes Anti-angina drug seems to be more effective for patients with worse glycemic control. Ranolazine reduces chest pain in patients with type 2 ...
On page 453, information summarizing the efficacy of ranolazine in the ERICA trial was reported incorrectly. The correct information is: Statistically significant decreases in angina attack frequency ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback